You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Hedgehog Inhibitor

Showing 51 - 75 of 7,424
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Her-2 Negative Breast Cancer, HRR Gene Mutation Trial in Guangzhou (Camrelizumab, Fluzoparib, Nab-paclitaxel)

Recruiting
  • Her-2 Negative Breast Cancer
  • HRR Gene Mutation
  • Guangzhou, Guangdong, China
    First Affiliated Hospital, Sun Yat-Sen University
Mar 7, 2023

Breast Cancer Trial in Wuhan (Adebrelimab, dalpiciclib)

Recruiting
  • Breast Cancer
  • Wuhan, Hubei, China
    Tongji Hospital Affiliated of Tongji Medical College Huazhong Un
Nov 20, 2023

Examining the Effect of Endocrine Therapy on Aging

Recruiting
  • Breast Neoplasm Female
  • +2 more
  • Aromatase inhibitor
  • Ann Arbor, Michigan
    University of Michigan Rogel Cancer Center
Jan 17, 2023

Healthy Male Trial in Shanghai (D-1553)

Active, not recruiting
  • Healthy Male
  • Shanghai, Shanghai, China
    Shanghai Xuhui District Central Hospital
Oct 23, 2023

Metastatic Breast Cancer Trial in Seoul (Fulvestrant plus AI plus ribociclib, AI plus ribociclib)

Not yet recruiting
  • Metastatic Breast Cancer
  • Fulvestrant plus AI plus ribociclib
  • AI plus ribociclib
  • Seoul, Korea, Republic of
    Korea university Guro hospital
Apr 16, 2023

Diabetes, Cellular Senescence, Sodium-Glucose Transporter 2 Inhibitors Trial in Seoul (SGLT2 inhibitor, Glimepiride)

Not yet recruiting
  • Diabetes Mellitus
  • +2 more
  • Seoul, Korea, Republic of
    Yonsei University College of Medicine
Aug 1, 2023

Neurofibromatosis 1, NF1, Neurofibromatosis Type 1 Trial in Chicago

Recruiting
  • Neurofibromatosis 1
  • +2 more
    • Chicago, Illinois
      Ann & Robert H. Lurie Children's Hospital of Chicago
    Mar 11, 2022

    Hidradenitis Suppurativa Trial in Tampa, Baton Rouge (Placebo, Izokibep)

    Recruiting
    • Hidradenitis Suppurativa
    • Tampa, Florida
    • +1 more
    Jun 20, 2023

    Relapsed/ Refractory Multiple Myeloma Trial in Worldwide (Talquetamab, Teclistamab, PD-1 Inhibitor)

    Recruiting
    • Relapsed/ Refractory Multiple Myeloma
    • Denver, Colorado
    • +19 more
    Jan 27, 2023

    Pancreatic Tumors, Stomach Tumors, Bile Duct Tumors Trial in Stockholm (68Ga-FAPI-46, PET/CT)

    Recruiting
    • Pancreatic Neoplasms
    • +3 more
    • Stockholm, Sweden
      Karolinska University Hospital Huddinge
    Dec 13, 2021

    Health Care Interventions and Outcomes of Major Bleedings in

    Not yet recruiting
    • Major Bleeding
    • None (Observational study)
    • (no location specified)
    Nov 17, 2023

    Tumor, Solid, Pancreatic Cancer Trial in Chapel Hill (Ulixertinib, Palbociclib)

    Recruiting
    • Tumor, Solid
    • +2 more
    • Chapel Hill, North Carolina
      Lineberger Comprehensive Cancer Center
    Nov 30, 2022

    Waldenstrom Macroglobulinemia, B-Cell Lymphoproliferative Disorder Trial in Boston (Pirtobrutinib, Venetoclax, Allopurinol)

    Not yet recruiting
    • Waldenstrom Macroglobulinemia
    • B-Cell Lymphoproliferative Disorder
    • Boston, Massachusetts
    • +2 more
    Feb 18, 2023

    Ovarian Cancer Recurrent Trial in Birmingham (M4344+Niraparib)

    Not yet recruiting
    • Ovarian Cancer Recurrent
    • Birmingham, Alabama
      University of Alabama at Birmingham
    Jan 5, 2023

    Non Small Cell Lung Cancer, KRAS Activating Mutation Trial in United States (VS-6766 and sotorasib)

    Recruiting
    • Non Small Cell Lung Cancer
    • KRAS Activating Mutation
    • avutometinib (VS-6766) and sotorasib
    • Washington, District of Columbia
    • +6 more
    Jan 31, 2023

    Determine Pro-Inflammatory Cytokine Kinetics During Immune

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • Melanoma
      • Indianapolis, Indiana
        Indiana University Melvin and Bren Simon Comprehensive Cancer Ce
      Jan 30, 2023

      Toxic Epidermal Necrolysis Trial in Fuzhou (Abrocitinib)

      Recruiting
      • Toxic Epidermal Necrolysis
      • Fuzhou, Fujian, China
        Department of Dermatology, the First Affiliated Hospital of Fuji
      Oct 31, 2023

      Paroxysmal Nocturnal Hemoglobinuria (PNH) Trial in Worldwide (BCX9930, Eculizumab, Ravulizumab)

      Active, not recruiting
      • Paroxysmal Nocturnal Hemoglobinuria (PNH)
      • Paris, France
      • +6 more
      Dec 15, 2022

      NSCLC Trial in Worldwide (Tepotinib, Osimertinib)

      Active, not recruiting
      • Non-small Cell Lung Cancer
      • Yuma, Arizona
      • +178 more
      Dec 19, 2022

      Depressive Disorder, Major Trial in Worldwide (Esketamine, SSRI/SNRI)

      Active, not recruiting
      • Depressive Disorder, Major
      • Ciudad Autonoma de Buenos Aires, Argentina
      • +58 more
      Jan 31, 2023

      Breast Cancer Trial in Guangzhou (Capecitabine, Aromatase Inhibitor)

      Active, not recruiting
      • Breast Cancer
      • Guangzhou, Guangdong, China
        State Key Laboratory of Oncology in South China, Sun Yat-sen Uni
      Jan 27, 2023

      Advanced Solid Tumor Trial in Beijing (Inosine 0.2g orally 3 times/day, PD-1/PD-L1 inhibitor ,chemo/targeting)

      Completed
      • Advanced Solid Tumor
      • Inosine 0.2g orally 3 times/day
      • PD-1/PD-L1 inhibitor ,chemotherapy/targeting
      • Beijing, Beijing, China
        Qin li
      Mar 30, 2023

      NSCLC Trial in Worldwide (JTX-4014, Vopratelimab)

      Active, not recruiting
      • NSCLC
      • Minsk, Belarus
      • +70 more
      Jan 18, 2023

      Circulating Tumor DNA and BRCA Reversion Mutation in Advanced or

      Recruiting
      • Ovarian Cancer
        • Seoul, Korea, Republic of
          Yonsei University Health System, Severance Hospital
        Jul 13, 2022

        Non Small Cell Lung Cancer, Urothelial Cancer, Renal Cell Carcinoma Trial in Worldwide (INCB086550)

        Active, not recruiting
        • Non Small Cell Lung Cancer
        • +4 more
        • Burgas, Bulgaria
        • +19 more
        Oct 20, 2022